Alnylam is also a member of Regeneron’s pre-competitive consortium to sequence the DNA of 500,000 ... MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung ...

BASKING RIDGE, N.J. & RAHWAY, N.J.--(BUSINESS WIRE)--The HERTHENA-Lung02 phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...

(RTTNews) - Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in patients with EGFR-mutated non-small cell lung cancer ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung ...

MSD and Daiichi Sankyo's patritumab deruxtecan hit its main objective in a phase 3 lung cancer study that reinforces its potential as a new treatment option for patients after first-line treatment ...

Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) announced Tuesday that their jointly developed lung cancer drug patritumab deruxtecan, which belongs to a new class of targeted cancer drugs ...

The safety profile in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer trials. The majority of interstitial lung disease (ILD) events were low ...